The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|September 2, 2011
- Pharmaceutical Technology-09-02-2011
- Volume 35
- Issue 9
Pharmaceutical Technology, September 2011 Issue (PDF)
Click the title above to open the Pharmaceutical Technology September 2011 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 15 years ago
A Design of Experiments for Tablet Compressionabout 15 years ago
Q&A with John Plachetka, POZENabout 15 years ago
Surface Neutralization Systemabout 15 years ago
Washington Report: Manufacturers and FDA Gear Up for User-Fee Actionabout 15 years ago
Knowing is Half the Battleabout 15 years ago
Retrospection and Introspection at FDAabout 15 years ago
Web 2.0 for Pharma Innovationabout 15 years ago
FDA Perspectives: Understanding Challenges to Quality by Designabout 15 years ago
Report from Latin Americaabout 15 years ago
The EU Debt Crisis and CMOsAdvertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AI Formulation: Regulators Want Data
5